Abstract
Purpose
To evaluate the effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure (IOP) due to tight orbit syndrome and to identify factors affecting the development of tight orbit syndrome in glaucoma patients.
Methods
We investigated 84 eyes in 84 glaucoma patients, of which 14 eyes were classified in the tight orbit syndrome group and 70 eyes in the control group. IOP was measured using the ICare tonometer and the Goldmann applanation tonometer (GAT). The demographic data, medical histories, ocular histories, and detailed ocular drug histories of the two groups were compared to identify factors contributing to the development of tight orbit syndrome.
Results
In the tight orbit syndrome group, the ICare tonometer significantly underestimated the IOP by approximately 8.6 mmHg compared with the GAT. In the control group, the IOP readings of the GAT and the ICare tonometer did not differ significantly. Bland–Altman analysis showed that the mean difference between measurements taken using the GAT and those taken using the ICare tonometer was 2.5 ± 6.3 mmHg. The difference between the GAT and ICare tonometer measurements was greater in the tight orbit syndrome group (8.6 ± 5.3 mmHg) than in the control group (1.3 ± 2.7 mmHg). Multivariate regression analysis revealed that only the use of prostaglandin analogs (PGAs) was associated with the development of tight orbit syndrome.
Conclusions
The ICare tonometer is a suitable alternative device for use in patients with tight orbit syndrome in whom the IOP may be overestimated with the GAT. The prolonged use of PGAs is significantly associated with the development of tight orbit syndrome.
Similar content being viewed by others
References
Kass MA. Standardizing the measurement of intraocular pressure for clinical research. Guidelines from the Eye Care Technology Forum. Ophthalmology. 1996;103:183–5.
Whitacre MM, Stein R. Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol. 1993;38:1–30.
Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg. 2005;31:156–62.
Iester M, Mermoud A, Achache F, Roy S. New Tonopen XL: comparison with the Goldmann tonometer. Eye (Lond). 2001;15:52–8.
Dekking HM, Coster HD. Dynamic tonometry. Ophthalmologica. 1967;154:59–74.
Kontiola A. A new electromechanical method for measuring intraocular pressure. Doc Ophthalmol. 1996;93:265–76.
Davies LN, Bartlett H, Mallen EA, Wolffsohn JS. Clinical evaluation of rebound tonometer. Acta Ophthalmol Scand. 2006;84:206–9.
Lee GA, Ritch R, Liang SY, Liebmann JM, Dubois P, Bastian-Jordan M, et al. Tight orbit syndrome: a previously unrecognized cause of open-angle glaucoma. Acta Ophthalmol. 2010;88:120–4.
Sahin A, Basmak H, Niyaz L, Yildirim N. Reproducibility and tolerability of the ICare rebound tonometer in school children. J Glaucoma. 2007;16:185–8.
Nakamura M, Darhad U, Tatsumi Y, Fujioka M, Kusuhara A, Maeda H, et al. Agreement of rebound tonometer in measuring intraocular pressure with three types of applanation tonometers. Am J Ophthalmol. 2006;142:332–4.
Brusini P, Salvetat ML, Zeppieri M, Tosoni C, Parisi L. Comparison of ICare tonometer with Goldmann applanation tonometer in glaucoma patients. J Glaucoma. 2006;15:213–7.
Salim S, Du H, Wan J. Comparison of intraocular pressure measurements and assessment of intraobserver and interobserver reproducibility with the portable ICare rebound tonometer and Goldmann applanation tonometer in glaucoma patients. J Glaucoma. 2013;22:325–9.
Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol. 2003;14:65–9.
Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53[Suppl 1]:93–105.
Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47[Suppl 1]:105–15.
Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302–7.
Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost: can bimatoprost cause enophthalmos? (in German). Klin Monbl Augenheilkd. 2008;225:443–5.
Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25:471–2.
Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176–9.
Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22–7.
Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55:600–4.
Peplinski LS. Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574–7.
Lepak NM, Serrero G. Prostaglandin F2 alpha stimulates transforming growth factor-alpha expression in adipocyte precursors. Endocrinology. 1995;136:3222–9.
Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998;273:1855–8.
Hou X, Arvisais EW, Jiang C, Chen DB, Roy SK, Pate JL, et al. Prostaglandin F2alpha stimulates the expression and secretion of transforming growth factor B1 via induction of the early growth response 1 gene (EGR1) in the bovine corpus luteum. Mol Endocrinol. 2008;22:403–14.
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286–92.
Nagase T, Uozumi N, Ishii S, Kita Y, Yamamoto H, Ohga E, et al. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med. 2002;8:480–4.
Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest. 1992;90:1–7.
Kanno Y, Kawashita E, Kokado A, Okada K, Ueshima S, Matsuo O, et al. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F2alpha synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2). Arthritis Rheum. 2013;65:492–502.
Ding WY, Ti Y, Wang J, Wang ZH, Xie GL, Shang YY, et al. Prostaglandin F2alpha facilitates collagen synthesis in cardiac fibroblasts via an F-prostanoid receptor/protein kinase C/Rho kinase pathway independent of transforming growth factor beta1. Int J Biochem Cell Biol. 2012;44:1031–9.
Scuderi G, Romano MR, Perdicchi A, Cascone N, Lograno M. Apraclonidine hydrochloride: pharmacology and clinical use. Expert Rev Ophthalmol. 2008;3:149–53.
Abraham LM, Epasinghe NC, Selva D, Casson R. Comparison of the ICare rebound tonometer with the Goldmann applanation tonometer by experienced and inexperienced tonometrists. Eye (Lond). 2008;22:503–6.
Jorge JM, González-Méijome JM, Queirós A, Fernandes P, Parafita MA. Correlations between corneal biomechanical properties measured with the ocular response analyzer and ICare rebound tonometry. J Glaucoma. 2008;17:442–8.
Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Garcia-Sanchez J. Reproducibility and clinical evaluation of rebound tonometry. Invest Ophthalmol Vis Sci. 2005;46:4578–80.
Acknowledgments
The authors thank E-World Editing for editing the final version of the manuscript.
Conflicts of interest
Y. K. Lee, None; J. Y. Lee, None; J. I. Moon, None; M. H. Park, None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Lee, Y.K., Lee, J.Y., Moon, J.I. et al. Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome. Jpn J Ophthalmol 58, 496–502 (2014). https://doi.org/10.1007/s10384-014-0343-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-014-0343-3